Abstract: The present invention provides novel compounds useful in modulating the protein tyrosine kinase activity, and in modulating inter—and/or intra—cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Abstract: This invention relates to a bromo-phenyl substituted thiazolyl dihydropyrimidine, its preparation method and use as a medicament for treating and preventing hepatitis B infections. The invention also relates to a composition comprising the dihydropyrimidine, one or more antiviral agents and, optionally, an immunomodulator for treating and preventing HBV infections.
Type:
Grant
Filed:
June 18, 2008
Date of Patent:
August 7, 2012
Assignee:
Sunshine Lake Pharma Co., Ltd.
Inventors:
Siegfried Goldmann, Jing Li, Yi Song Liu
Abstract: Crystalline pyridone compound, which is the white needle crystal containing no water and other crystallization solvents. Its unit cell belongs to monoclinic system and has space group of P21/n, wherein a=3.8512(2), b=20.2535(12), c=12.1628(6) ?, ?=92.850(5)° and crystal cell volume V=947.53(9) ?3. Pyridone compound crystal of this form has the needed properties for preparing or making treatment compositions in large scale. It can be used for treating organs fibrosis of liver, kidney, lung and etc. and reducing skin scars.
Abstract: Farnesene interpolymer comprises units derived from a farnesene (e.g., ?-farnesene or ?-farnesene) and units derived from at least one vinyl monomer. The farnesene interpolymer can be prepared by copolymerizing the farnesene and at least one vinyl monomer in the presence of a catalyst. In some embodiments, the farnesene is prepared from a sugar by using a microorganism. In other embodiments, the at least one vinyl monomer is ethylene, an ?-olefin, or a substituted or unsubstituted vinyl halide, vinyl ether, acrylonitrile, acrylic ester, methacrylic ester, acrylamide or methacrylamide, or a combination thereof.
Abstract: A low-emissions high-pressure multi-fuel burner includes a fuel inlet, for receiving a fuel, an oxidizer inlet, for receiving an oxidizer gas, an injector plate, having a plurality of nozzles that are aligned with premix face of the injector plate, the plurality of nozzles in communication with the fuel and oxidizer inlets and each nozzle providing flow for one of the fuel and the oxidizer gas and an impingement-cooled face, parallel to the premix face of the injector plate and forming a micro-premix chamber between the impingement-cooled face and the in injector face. The fuel and the oxidizer gas are mixed in the micro-premix chamber through impingement-enhanced mixing of flows of the fuel and the oxidizer gas. The burner can be used for low-emissions fuel-lean fully-premixed, or fuel-rich fully-premixed hydrogen-air combustion, or for combustion with other gases such as methane or other hydrocarbons, or even liquid fuels.
Type:
Grant
Filed:
April 28, 2006
Date of Patent:
June 12, 2012
Assignee:
The United States of America, as represented by the Administrator of the National Aeronautics and Space Administration